埃克替尼一线治疗EGFR敏感性突变的晚期非小细胞肺癌的疗效观察  

Efficacy of icotinib as first-line therapy in advanced NSCLC patients with sensitive EGFR mutation

作　　者：林动[1] 许凌[1] 林景辉[1] 何志勇[1] 徐海鹏[1] 王强[1] 

机构地区：[1]福建省肿瘤医院胸部肿瘤内科,福建福州350014

出　　处：《实用肿瘤杂志》2015年第3期220-224,共5页Journal of Practical Oncology

基　　金：国家临床重点专科建设项目资助

摘　　要：目的探讨盐酸埃克替尼一线治疗EGFR敏感性突变的晚期NSCLC的疗效及安全性。方法回顾性分析51例使用埃克替尼治疗的EGFR敏感性突变的晚期非小细胞肺癌患者,口服埃克替尼125 mg,3次/d,持续至疾病进展或不良反应无法耐受,计算有效率、疾病控制率、中位生存期、无进展生存期以及不良反应。结果 51例患者中19外显子缺失突变29例,21外显子错义突变22例,有效率为70.6%,疾病控制率88.2%;中位生存期为29.0月,无进展生存期为10.5月;主要不良反应是皮疹和腹泻,多为Ⅰ~Ⅱ级。结论埃克替尼一线治疗EGFR敏感性突变的晚期非小细胞肺癌有较好的疗效,不良反应较轻,为一线治疗EGFR敏感性突变的晚期非小细胞肺癌的新选择。Objective To evaluate the efficacy of icotinib as first-line therapy in advanced non-small-cell lung cancer（ NSCLC） patients with sensitive EGFR mutation. Methods Clinical data of 51 advanced NSCLC patients with sensitive EGFR mutation receiving icotinib treatment were retrospectively reviewed. Patients were treated with icotinib 125 mg,po,tid. until disease progression or unacceptable toxicity. Efficacy and adverse effects were analyzed. Results Among51 patients,exon 19 deletion was detected in 29 cases,exon 21 mutations in 22. The overall response rate（ ORR） was70. 6% and the disease control rate（ DCR） was 88. 2%. The median progression-free survival（ PFS） was 10. 5 months and the median overall survival was 29. 0 months. Adverse effects were generally mild and consisted of rash and diarrhea.Conclusion Icotinib as first-line therapy shows significant antitumor activity in advanced NSCLC with EGFR sensitive mutation. Toxicity was well tolerated and acceptable.

关 键 词：肺肿瘤/药物疗法 癌 非小细胞肺/药物疗法 受体 表皮生长因子 突变 酶抑制剂/治疗应用 治疗结果 回顾性研究 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]